Research Projects & Grants

For Profit Organization

  • CAMP III - A randomized, double-blind, parallel-group study to assess the safety and efficacy of Asacol® (1.2 to 4.8g/day) 400 mg delayed-release tablets given twice a day for 26 weeks to children and adolescents for the maintenaince of remission of ulcerative colitis, Role: Investigator, Procter & Gamble Company, (09/2010 - 09/2011) Status: Completed

Internal

  • Giving feedback-learned?, Role: Investigator, LLU Dept. of Pediatrics, (06/2012) Status: Completed